These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11032540)

  • 21. The year in non-ST-segment elevation acute coronary syndromes.
    Giugliano RP; Braunwald E
    J Am Coll Cardiol; 2005 Sep; 46(5):906-19. PubMed ID: 16139143
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute coronary syndrome: new advances and nursing strategies.
    Palatnik AM
    Dimens Crit Care Nurs; 2000; 19(5):22-6. PubMed ID: 11998062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines.
    Young JJ; Choo JK; Kereiakes DJ; ;
    J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626
    [No Abstract]   [Full Text] [Related]  

  • 24. [Acute coronary syndromes without ST-segment elevation. From randomized clinical trials, to consensus guidelines, to clinical practice in Italy: need to close the circle].
    Savonitto S; Klugmann S
    Ital Heart J Suppl; 2004 Mar; 5(3):167-76. PubMed ID: 15116860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Landolfi R; De Cristofaro R
    Lancet; 2002 Jul; 360(9328):257. PubMed ID: 12133682
    [No Abstract]   [Full Text] [Related]  

  • 26. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Meier JJ; Gallwitz B; Schmidt WE; Nauck MA
    Lancet; 2002 Jul; 360(9328):257. PubMed ID: 12133683
    [No Abstract]   [Full Text] [Related]  

  • 27. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.
    Robinson M; Ginnelly L; Sculpher M; Jones L; Riemsma ; Palmer S; Philips Z; Glanville J
    Health Technol Assess; 2002; 6(25):1-160. PubMed ID: 12583818
    [No Abstract]   [Full Text] [Related]  

  • 28. [Inhibitors of platelet receptors GP IIB/IIIA: a new therapeutic class and its promise in the treatment of acute coronary syndromes].
    Yerna M; Legrand V; Kulbertus H
    Rev Med Liege; 1997 May; 52(5):329-35. PubMed ID: 9273634
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
    Vorchheimer DA; Fuster V
    Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
    [No Abstract]   [Full Text] [Related]  

  • 30. Glycoprotein IIb/IIIa inhibitors.
    Herbert ME; Brewster GS
    Ann Emerg Med; 1999 Sep; 34(3):407-10. PubMed ID: 10459103
    [No Abstract]   [Full Text] [Related]  

  • 31. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword?
    Quinn MJ; Plow EF; Topol EJ
    Circulation; 2002 Jul; 106(3):379-85. PubMed ID: 12119257
    [No Abstract]   [Full Text] [Related]  

  • 32. Glycoprotein IIb/IIIa platelet receptor blockers: are they ready for prime time in patients with unstable coronary artery disease?
    Conti CR
    Clin Cardiol; 1999 Feb; 22(2):57-8. PubMed ID: 10068840
    [No Abstract]   [Full Text] [Related]  

  • 33. The evolution of oral antiplatelet therapy.
    Timmis SB; O'Neill WW
    Semin Interv Cardiol; 1999 Jun; 4(2):89-95. PubMed ID: 10473878
    [No Abstract]   [Full Text] [Related]  

  • 34. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
    Kaul P; Newby LK; Fu Y; Hasselblad V; Mahaffey KW; Christenson RH; Harrington RA; Ohman EM; Topol EJ; Califf RM; Van de Werf F; Armstrong PW;
    J Am Coll Cardiol; 2003 Feb; 41(3):371-80. PubMed ID: 12575962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet therapy in acute coronary syndromes without persistent ST-segment elevation.
    Jain D; Katus HA; Richardt G
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):423-36. PubMed ID: 11855661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical impact of platelet glycoprotein IIb/IIIa receptor blockade in cardiovascular medicine.
    Mak KH; Tan AT; Chan C; Koh TH; Topol EJ
    Jpn Circ J; 1998 Apr; 62(4):233-43. PubMed ID: 9583455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advance on clinical applications of platelet glycoprotein IIb/IIIa receptor inhibitors].
    Zhou P; Yan HB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):274-7. PubMed ID: 21609538
    [No Abstract]   [Full Text] [Related]  

  • 38. More drugs pass the NICE test.
    MacDonald R
    BMJ; 2000 Oct; 321(7265):853. PubMed ID: 11021859
    [No Abstract]   [Full Text] [Related]  

  • 39. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 40. Glycoprotein IIb/IIIa integrin blockade.
    Madan M; Berkowitz SD; Tcheng JE
    Circulation; 1998 Dec; 98(23):2629-35. PubMed ID: 9843473
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.